AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

London, UK, Friday 30 May 2025 – Today, AstraZeneca announced that the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga ...

• Use of the AstraZeneca Dapagliflozin Patient Identification Resource (DAPA-id) to identify patients in your practice who may benefit from taking dapagliflozin. • Opportunities to improve your ...

AstraZeneca Pharma India on Monday said it has received approval for extended indication from the Drugs Controller General of India for Dapagliflozin 10 mg tablets. View in App The receipt of this ...

2.1 Dapagliflozin (Forxiga, AstraZeneca) is indicated in adults for 'the treatment of symptomatic chronic heart failure'. 2.2 Dapagliflozin is recommended for treating chronic heart failure with ...

astrazeneca | dapagliflozin | heart failure. Related posts. Levicept presents new LEVI-04 data at EULAR. Jun 12, 2025. Migraine takes the spotlight at European Parliament. Jun 12, 2025. Bimekizumab ...

Ed Piper, Medical and Scientific Affairs Director, AstraZeneca UK, said: “We’re delighted that the MHRA has authorised dapagliflozin for use in heart failure with preserved ejection fraction. We ...

AstraZeneca on Wednesday announced that its dapagliflozin has significantly reduced the risk of cardiovascular death and heart failure, as per the outcomes of the DELIVER Phase III trial.

AstraZeneca's dapagliflozin meets primary endpoint in DELIVER phase III trial DELIVER is the largest and broadest trial to date in heart failure with mildly reduced or preserved ejection fraction.

In hospitalized patients with COVID-19, the SGLT2 inhibitor dapagliflozin was well tolerated regardless of kidney function, but did not significantly lower patients’ risk of organ failure ...

The voluntary withdrawal of the type 1 diabetes indication for dapagliflozin in the EU by AstraZeneca has been branded as 'appalling' and 'devastating', with questions raised as to why it was pulled.